Key Highlights
- ARK Invest divested 37,977 shares of AMD valued at approximately $18.1 million on Wednesday
- The firm acquired 57,705 shares of Broadcom and 69,585 shares of Cerebras Systems as semiconductor replacements
- ARK offloaded 59,276 shares of Tempus AI via its ARKK ETF worth over $4 million
- The investment firm purchased 47,793 shares of Veracyte totaling $2.1 million distributed between ARKK and ARKG ETFs
- Additional position reductions included Twist Bioscience, Roblox, and Brera Holdings
Cathie Wood’s investment firm ARK Invest has executed significant portfolio adjustments throughout this week, liquidating substantial technology holdings while simultaneously establishing fresh positions in biotechnology and artificial intelligence semiconductor companies.
The most notable transaction occurred on Wednesday with ARK divesting 37,977 shares of Advanced Micro Devices, representing approximately $18.1 million in value. AMD stock concluded trading down 0.9% at $476.67 during that session.
Advanced Micro Devices, Inc., AMD
This divestment reflects an ongoing pattern. Wood has been progressively reducing ARK’s AMD holdings throughout recent months, despite the stock delivering gains exceeding 100% year-to-date.
Seeking to maintain AI semiconductor exposure, ARK acquired 57,705 shares of Broadcom alongside 69,585 shares of Cerebras Systems during the identical trading session. Broadcom stock advanced 4.5% to close at $371.54, while Cerebras gained 2.5% finishing at $186.67.
Notably, ARK maintains a larger AMD position compared to these recent additions. The prominent ARK Innovation ETF currently holds $193.3 million in AMD, contrasted with $149.5 million in Cerebras and $95.3 million in Broadcom.
Tempus AI Position Reduced Following Multiple Transactions
Thursday witnessed ARK disposing of an additional 59,276 shares of Tempus AI through its ARKK ETF, representing slightly more than $4 million. This transaction continues a series of Tempus AI reductions executed earlier during the week.
The firm additionally sold 22,225 shares of Twist Bioscience distributed across its ARKK and ARKG ETFs, totaling $3.3 million. These divestments represent a recurring action throughout the recent trading period.
Minor position cuts encompassed 1,001 shares of Roblox valued at $37,597 and 29,385 shares of Brera Holdings worth $116,658.
Biotechnology Sector Receives Increased Allocation
Regarding acquisitions, ARK purchased 47,793 shares of Veracyte representing $2.1 million, distributed between its ARKK and ARKG portfolios. This transaction signals increasing conviction in the cancer diagnostics specialist.
ARK furthermore acquired 5,085 shares of Scribe Therapeutics through its ARKG ETF for $161,194, extending an established biotech investment trajectory.
These transactions demonstrate ARK reallocating capital from select technology holdings toward genomics and biotechnology sectors, areas that have consistently remained fundamental to Wood’s investment philosophy.
Wood established ARK’s industry reputation through concentrated investments in specialized sectors including genomics, robotics, and artificial intelligence, notably featuring an early Tesla stake. Nevertheless, the flagship ARKK fund has registered an annualized decline of approximately 9% throughout the preceding five-year period.
The current transaction activity indicates Wood is implementing another strategic repositioning, reducing exposure to AMD and Tempus AI while expanding holdings in Broadcom, Cerebras, and Veracyte.
ARK’s ARKK ETF finished Thursday’s session up 1.87% while its ARKG ETF advanced 0.85%.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
